Welcome to our dedicated page for Nextcure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on Nextcure stock.
NextCure, Inc. develops targeted cancer therapies as a clinical-stage biopharmaceutical company, with news centered on antibody-drug conjugate programs and related financial updates. Its principal update themes include SIM0505, a Cadherin-6-directed ADC with a topoisomerase 1 inhibitor payload, and LNCB74, a B7-H4-directed ADC.
Company announcements also cover clinical data presentations, FDA interactions such as Fast Track designation for SIM0505 in platinum-resistant ovarian cancer, collaborations with Simcere Zaiming, business updates, financial results, and participation in healthcare investor conferences.
NextCure (Nasdaq:NXTC) announced that a replay of its virtual key opinion leader (KOL) event on SIM0505 is now available. The event followed ASCO 2026 dose escalation data from the Phase 1 trial in ovarian cancer and uterine serous carcinoma.
Experts discussed first reported clinical efficacy data for these difficult-to-treat gynecologic cancers.
NextCure (Nasdaq:NXTC) and partner Simcere Zaiming reported positive Phase 1 dose escalation data for SIM0505, an anti-CDH6 ADC, in advanced gynecologic cancers at ASCO 2026.
Among therapeutic-dose patients (4.8–8.0 mg/kg) with ≥12 weeks follow-up, ORR was 55% in gynecologic cancers, 52.9% in ovarian and 66.7% in USC, with favorable overall safety in 59 heavily pretreated patients. A virtual KOL event is scheduled for June 2, 2026 at 8:00 AM ET.
NextCure (Nasdaq: NXTC) reported Q1 2026 results and a business update on May 7, 2026. Key clinical progress: FDA Fast Track designation for SIM0505 in platinum-resistant ovarian cancer, Phase 1 dose-escalation data to be presented at ASCO 2026 on June 1, 2026, and initiation of a dose-optimization study. Cash totaled $29.7M at March 31, 2026, with runway expected into the first half of 2027 through SIM0505 proof-of-concept.
NextCure (Nasdaq: NXTC) and Simcere Zaiming initiated the dose optimization portion of the Phase 1 study of SIM0505, an investigational CDH6-targeting ADC, focused initially on patients with platinum-resistant ovarian cancer (PROC).
The program will expand U.S. and China trial sites and add sites in Canada and Europe. Phase 1 data readout is planned for ASCO 2026.
NextCure (Nasdaq: NXTC) and Simcere will present Phase 1 data for SIM0505, an anti-CDH6 antibody-drug-conjugate (ADC), as a poster at ASCO 2026.
The poster (Abstract #5580, Board 246) will be presented June 1, 2026, by Xiaohua Wu, MD, PhD; the poster will be posted on the company investor site after the session.
NextCure (Nasdaq: NXTC) announced the FDA granted Fast Track designation to SIM0505, an anti-CDH6 antibody-drug conjugate, for treatment of platinum-resistant ovarian cancer.
The company plans to begin dose optimization in Q2 2026 and will present Phase 1 data at ASCO 2026, enabling closer FDA engagement to accelerate development.
NextCure (Nasdaq: NXTC) and Simcere announced that an abstract for SIM0505 (CDH6 ADC) was accepted for presentation at ASCO 2026, held May 29–June 2 in Chicago. SIM0505 is an investigational ADC targeting Cadherin-6 (CDH6) with a proprietary TOPOi payload.
The ongoing open-label Phase 1 study (NCT06792552) is evaluating SIM0505 in advanced solid tumors, including ovarian cancer, with emphasis on platinum-resistant ovarian cancer.
NextCure (Nasdaq: NXTC) provided a business update and reported full-year 2025 results on March 5, 2026. Key clinical milestones include SIM0505 Phase 1 dose escalation data expected Q2 2026 and initiation of a Phase 1 dose optimization study in platinum resistant ovarian cancer in Q2 2026. LNCB74 enrollment continues with a trial update planned H2 2026. Financials: $41.8M cash at year-end and net loss of $55.8M for 2025; company expects runway into H1 2027 through SIM0505 proof-of-concept.
NextCure (NASDAQ: NXTC) provided a business update on Jan 23, 2026, reporting clinical progress for two ADC programs and a preliminary year-end cash position.
SIM0505 (CDH6 ADC): Phase 1 dose-escalation data from U.S. and China cohorts are expected in Q2 2026; company is adding sites and increasing drug supply to start dose optimization in H1 2026. LNCB74 (B7-H4 ADC): dose escalation expanded into higher cohorts with prioritization of high B7-H4 breast and gynecological cancer patients; proof-of-concept timing delayed to a trial update in 2H 2026. Financials: preliminary cash and equivalents approx $41.8M, expected to fund operations into 1H 2027.
NextCure (Nasdaq: NXTC) will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City on Wednesday, December 3, 2025 at 11:00 AM ET.
A live audio webcast will be available via the company's Investors website and a replay will be archived on the site for 30 days after the event.